Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: A substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial

Journal of the American College of Cardiology

Volumn 43, Issue 12, 2004, Pages 2200-2206

  Lonn, Eva ^a,b,d   Shaikholeslami, Roya ^a,b   Yi, Qilong ^b,c   Bosch, Jackie ^b   Sullivan, Brian ^a   Tanser, Paul ^a   Magi, Alison ^b   Yusuf, Salim ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

ACE; American Society of Echocardiography; angiotensin converting enzyme; ASE; blood pressure; BP; Heart Outcomes Prevention Evaluation trial; HOPE; left ventricle ventricular; left ventricular end diastolic volume; LV; LVEDV; LVEF

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 2942518221     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.10.073     Document Type: Article

References (29)

1. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352
2. Ghali J.K., Liao Y., Simmons B., et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med. 117:1992;831-836
3. Lonn E., Mathew J., Pogue J., et al. Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. J Cardiovasc Risk. 10:2003;420-428
4. Sundström J., Lind L., Ärnlöv J., et al. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation. 103:2001;2346-2351
5. Levy D., Garrison R.J., Savage D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart study. N Engl J Med. 322:1990;1561-1566
6. White H.D., Norris R.M., Brown M.A., et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 76:1987;44-51
7. Multicenter Postinfarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med. 309:1983;331-336
8. St. John Sutton M., Pfeffer M., Plappert T., et al. SAVE Investigators. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction The protective effects of captopril. Circulation. 89:1994;68-75
9. Nagano M., Higaki J., Mikami H., et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens. 9:1991;595-599
10. Agabati-Rosei E., Ambriosoni E., Dal Palu C., et al. RACE Study Group. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension Results of the race (ramipril cardioprotective evaluation) study. J Hypertens. 13:1995;1325-1334
11. Schmieder R.E., Schlaich M.P., Klingbeil A.U. Reversal of left ventricular hypertrophy in essential hypertension A meta-analysis of randomized double-blind studies. JAMA. 275:1996;1507-1513
12. Greenberg B., Quinones M.A., Koipillai C., et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Circulation. 91:1995;2573-2581
13. Lonn E.M., Yusuf S., Jha P., et al. Emerging role of angiotensin- converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069
14. Dzau V.J., Berstien K., Celermajer D., et al. The relevance of tissue ACE Manifestations in mechanistic and endpoint data. Am J Cardiol. 88:(Suppl):2001;1L-20L
15. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease A unifying hypothesis. Hypertension. 37:2001;1047-1052
16. The HOPE Investigators. The HOPE (Heart Outcomes Prevention Evaluation) study. The design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 12:1996;127-137
17. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 342:2000;145-153
18. Sahn D.J., DeMaria A., Kisslo J., et al. Recommendations regarding quantitation in M-mode echocardiography Results of a survey of echocardiographic measurements. Circulation. 58:1978;1072-1081
19. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy Comparison to necropsy findings. Am J Cardiol. 57:1986;450-458
20. Helak J.W., Reicheck N. Quantitation of human left ventricular mass and volume by two-dimensional echocardiography In vitro and anatomic validation. Circulation. 63:1981;1398-1407
21. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiography. 2:1989;358-367
22. Devereux R.B., Palmieri V., Sharpe N., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. Circulation. 104:2001;1248-1254
23. Mancia G., Zanchetti A., Agabati-Rosei E., et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment induced regression of left ventricular hypertrophy Sample study group: study on ambulatory monitoring of blood pressure and lisinopril evaluation. Circulation. 95:1997;1464-1470
24. Mathew J., Sleight P., Lonn E., et al. HOPE Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 104:2001;1615-1621
25. Havranek E.P., Esler A., Estacio O., et al. Differential effects of antihypertensive agents on electrocardiographic voltage Results from the appropriate blood pressure control in diabetes (abcd) trial. Am Heart J. 145:2003;993-998
26. Linz W., Scholkens B.A., Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens. 11:1989;1325-1350
27. Kaneko K., Susic D., Nunez E., et al. ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats. Am J Sci. 314:1997;21-27
28. Arnold M.J., Yusuf S., Young J., et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 107:2003;1284-1290
29. McDonald K., Mock J., D'Aloia A., et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition after discrete transmural necrosis. Circulation. 91:1995;2034-2048